Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

Stock Exchange Code 4530 April 26, 2019

To Shareholders with Voting Rights:

Hirotaka Nakatomi Chairman & CEO Hisamitsu Pharmaceutical Co., Inc. 408 Tashiro Daikan-machi, Tosu, Saga

# NOTICE OF CONVOCATION OF THE 117TH ANNUAL GENERAL MEETING OF SHAREHOLDERS

We would like to express our appreciation for your continued support and patronage.

You are cordially invited to attend the 117th Annual General Meeting of Shareholders of Hisamitsu Pharmaceutical Co., Inc. (the "Company"). The meeting will be held for the purposes as described below.

If you are unable to attend the meeting, you may exercise your voting rights in writing. In this case, please review the attached Reference Documents for the General Meeting of Shareholders, indicate your vote for or against the proposals on the enclosed Voting Rights Exercise Form and return it so that it is received by 5:00 p.m. on Wednesday, May 22, 2019, Japan time.

1. Date and Time: Thursday, May 23, 2019 at 10:00 a.m. Japan time

2. Place: Head office of the Company located at

408 Tashiro Daikan-machi, Tosu, Saga, Japan

3. Meeting Agenda:

Matters to be reported: 1. The Business Report, Consolidated Financial Statements and Non-

consolidated Financial Statements for the Company's 117th Fiscal Year

(March 1, 2018 - February 28, 2019)

2. Results of audits by the Independent Auditor and the Board of Corporate

Auditors of the Consolidated Financial Statements for the Company's 117th

Fiscal Year

Proposals to be resolved:

Proposal 1: Appropriation of Surplus Proposal 2: Election of 12 Directors

Proposal 3: Election of One Corporate Auditor

(The details of the meeting agenda and other matters are stated in the following pages.)

When attending the meeting, please submit the enclosed Voting Rights Exercise Form at the reception desk. In addition, you are requested to bring this Notice of Convocation of the General Meeting of Shareholders with you in order to save resources.

Any revisions to the Reference Documents for the General Meeting of Shareholders, Business Report, Non-consolidated Financial Statements or Consolidated Financial Statements will be posted on the Company's website (http://www.hisamitsu.co.jp).

# Reference Documents for the General Meeting of Shareholders

## Proposal 1: Appropriation of Surplus

The Company regards the appropriate return of profits to shareholders as one of the most important management issues.

With respect to dividends of surplus at the end of the fiscal year under review, upon comprehensively examining factors such as the performance for the fiscal year, dividend payout ratios and various management measures for the future in addition to taking into account the stable distribution of dividends to shareholders, the Company proposes to pay a dividend of \(\frac{\frac{41.25}}{41.25}\) per share as follows. Accordingly, the annual dividend including an interim dividend of \(\frac{\frac{41.25}}{41.25}\) will be \(\frac{\frac{482.5}}{482.5}\) per share, an increase from the annual dividend of \(\frac{482}{482}\) per share for the previous fiscal year.

In addition, the Company recognizes the need to strengthen its financial structure to provide for the stable return of profits to its shareholders and future business development, and therefore intends to allocate ¥10.0 billion to General reserve as follows.

- 1. Matters concerning dividends of surplus
- (1) Allotment of dividend properties to shareholders and the total amount thereof ¥41.25 per share of the Company's common stock Total payment of dividends: ¥3,411,057,664
- (2) Effective date of dividends of surplus Friday, May 24, 2019
- 2. Matters concerning appropriation of surplus
- (1) Surplus item to be increased and the amount thereof General reserve \quad\{\frac{1}{2}}10,000,000,000
- (2) Surplus item to be decreased and the amount thereof Retained earnings brought forward \$\gmu 10,000,000,000\$

# Proposal 2:

### Election of 12 Directors

The terms of office of all 12 Directors will expire at the conclusion of this General Meeting of Shareholders. Accordingly, the election of 12 Directors is proposed.

The candidates for Directors are as follows:

No.	Name	D	Past experience, positions, responsibilities	Number of	Special		
	(Date of birth)	and significant concurrent positions		shares of the	interests in the		
	(Bute of offth)	and significant concurrent positions		Company held	Company		
		February 1966	Joined the Company				
	Hirotaka Nakatomi (February 6, 1937)	April 1975	Director	177,732	None		
		May 1979	Managing Director				
		May 1981	President				
1	[Reappointment]	May 2006	President & Executive Officer				
1		May 2015	Chairman & CEO (to present)				
	[Reason for nomination as candidate]						
	Mr. Hirotaka Nakatomi has long been in charge of management of the Company as a Representative Director, and makes the						
	Board of Directors function effectively by leveraging his extensive experience and deep insight into all aspects of management.						
	We believe he is suitab	ole for continuing	to serve as a Director of the Company, and nominate him	as a candidate fo	r Director.		
		April 1999	Joined the Company				
	Kazuhide Nakatomi	February 2007	Head of Corporate Strategy Planning				
2	(June 30, 1972)	May 2007	Director & Executive Officer				
		May 2009	Managing Director & Executive Officer	237,942	None		
	[Reappointment]	May 2011	Senior Managing Director & Executive Officer				
		May 2014	Vice President & Executive Officer				
		May 2015	President & COO (to present)				

[Reason for nomination as candidate]

Mr. Kazuhide Nakatomi has extensive operational experience in the corporate strategy planning division, and took office as Director of the Company in 2007. He also has built track records as a corporate manager since he became President in 2015. We believe he is suitable for continuing to serve as a Director of the Company, and nominate him as a candidate for Director.

	Name	р	ast experience, positions, responsibilities	Number of	Special		
No.	(Date of birth)	and significant concurrent positions		shares of the	interests in the		
	(Date of office) and significant concurred		and significant concurrent positions	Company held	Company		
		April 1977	Joined the Company				
		May 1999	Director				
	Kousuke Sugiyama	February 2010	Director & Executive Officer		None		
	(April 28, 1952)	July 2012	Managing Director & Executive Officer	13,000			
		May 2014	Senior Managing Director & Executive Officer	15,000			
3	[Reappointment]	,	[In charge of Human Resources, BU, Hisamitsu				
)			Springs, Quality Assurance & Pharmacovigilance and				
1			Internal Audit] (to present)				
1	[Reason for nomination	-					
1		Mr. Kousuke Sugiyama has extensive operational experience in the human resources division, and has been managing and					
			uding human resources, since he took office as Director of				
	believe he is suitable for	or continuing to se	rve as a Director of the Company, and nominate him as a	candidate for Di	rector.		
		April 1974	Joined the Company				
	Tetsuo Akiyama	March 2003	Executive Officer		None		
	(May 16, 1951)	May 2007	Senior Executive Officer	7,000			
		May 2009	Director & Executive Officer	7,000	TVOILC		
4	[Reappointment]	March 2013	Managing Director & Executive Officer				
+			[In charge of Operation Division] (to present)				
l	[Reason for nomination as candidate]						
	Mr. Tetsuo Akiyama h	as extensive opera	tional experience in the sales division, and has been mana	aging and superv	ising sales		
1			ector of the Company in 2009. We believe he is suitable f	for continuing to	serve as a		
	Director of the Compar	•	nim as a candidate for Director.				
		April 1985	Joined the Company				
	Naruhito Higo (January 15, 1963)	March 2011	Executive Officer				
		May 2012	Director & Executive Officer				
	(January 13, 1703)	May 2014	Managing Director & Executive Officer	3,100	(Note 1)		
	[Reappointment]	May 2017	Director (part-time)				
5	[Keappointment]	-	[Board Chairman of Noven Pharmaceuticals, Inc.] (to				
			present)				
i	[Paggan for naminati	on as condidatal					

[Reason for nomination as candidate]
Mr. Naruhito Higo has extensive operational experience in the research and development division, and has been managing and supervising research and development activities both in Japan and abroad since he took office as Director of the Company in 2012. We believe he is suitable for continuing to serve as a Director of the Company, and nominate him as a candidate for Director.

No.	Name (Date of birth)	Past experience, positions, responsibilities and significant concurrent positions		Number of shares of the	Special interests in the		
	, ,		1	Company held	Company		
		April 1978	Joined the Company				
		April 2007	Executive Officer				
	Toshiaki Tsuruda	May 2011	Director & Executive Officer				
6	(May 10, 1955)		[Head of Production Division, Vice Chairman of Noven Pharmaceuticals, Inc., Director of Yutoku	7,100	None		
	[Reappointment]		Pharmaceutical Ind. Co., Ltd. (part-time) and Corporate Auditor of Maruto Sangyo Co., Ltd. (part-time)] (to				
			present)				
	[Reason for nomination as candidate]						
	Mr. Toshiaki Tsuruda has extensive operational experience in the production division, and has been managing and supervising						
	production activities of the entire Hisamitsu Pharmaceutical Group since he took office as Director of the Company in 2011. We						
	believe he is suitable for	or continuing to s	serve as a Director of the Company, and nominate him as a	candidate for Di	rector.		
		April 1978	Joined the Company				
	Shinichiro Takao	May 2007	Executive Officer				
7	(January 23, 1955)	May 2013	Director & Executive Officer				
		,	[Head of BU Division, General Manager of Finance	3,200	None		
	[Reappointment]		and Accounting, IR, CSR, President of Hisamitsu U.S.,				
			Inc. and Director of Yutoku Pharmaceutical Ind. Co.,				

[Reason for nomination as candidate]

Mr. Shinichiro Takao has extensive operational experience in the corporate strategy planning and finance and accounting divisions, and has been extensively managing and supervising back-office divisions, including finance and accounting, general affairs and information systems, since he took office as Director of the Company in 2013. We believe he is suitable for continuing to serve as a Director of the Company, and nominate him as a candidate for Director.

Ltd. (part-time)] (to present)

	Name	D	ast experience, positions, responsibilities	Number of	Special			
No.	(Date of birth)	г	and significant concurrent positions	shares of the	interests in the			
	(Date of ontif)		and significant concurrent positions	Company held	Company			
		April 1987	Joined the Company					
		April 2009	Executive Officer					
		May 2013	Director & Executive Officer					
	Kyu Saito		[Head of International Division, Chairman of Hisamitsu					
	(June 10, 1963)		America, Inc., President of Hisamitsu Pharmaceutical	3,800	None			
			Technology Consulting (Beijing) Co., Ltd., President of	3,800	None			
8	[Reappointment]		Hisamitsu Pharmaceutical (China) Co., LTD., President					
0			of Hisamitsu Pharmaceutical (Hong Kong) Co., Ltd.,					
			Chairman of Hisamitsu Italia S.r.l., and Director of P.T.					
			Hisamitsu Pharma Indonesia] (to present)					
	[Reason for nomination as candidate]							
	Mr. Kyu Saito has extensive operational experience in the sales and corporate strategy planning divisions, and has been							
	managing and supervising the overseas sales division since he took office as Director of the Company in 2013. We believe he is							
	suitable for continuing	to serve as a Dire	ctor of the Company, and nominate him as a candidate for	Director.				
	Nobuo Tsutsumi	April 1988	Joined the Company					
		March 2010	Executive Officer					
	(March 11, 1964)	May 2014	Director & Executive Officer	3,100	None			
	[Dannaintmant]		[General Manager of Legal and Compliance] (to					
9	[Reappointment]		present)					
	[Reason for nomination as candidate]							
	Mr. Nobuo Tsutsumi has extensive operational experience in the legal division, and has been managing and supervising legal							
	affairs and compliance based on his high expertise since he took office as Director of the Company in 2014. We believe he is							
	suitable for continuing to serve as a Director of the Company, and nominate him as a candidate for Director.							
		March 1991	Joined the Company					
	Shinichi Murayama	March 2012	Executive Officer					
	(October 16, 1967)	May 2014	Director & Executive Officer	3,000	None			
		-	[Executive Secretary of Chairman's Office and Outside	3,000	None			
	[Reappointment]		Corporate Auditor of SANOFI-HISAMITSU K.K.					
10			(part-time)] (to present)					
1	[Reason for nomination as candidate]							

[Reason for nomination as candidate]

Mr. Shinichi Murayama has extensive operational experience in the sales and corporate strategy planning divisions, and has been managing and supervising management in general as Executive Secretary of Chairman's Office since he took office as Director of the Company in 2014. We believe he is suitable for continuing to serve as a Director of the Company, and nominate him as a candidate for Director.

	Name	ī	Past experience, positions, responsibilities	Number of	Special
No.	(Date of birth)	and significant concurrent positions		shares of the	interests in the
			and significant concurrent positions	Company held	Company
	Isao Ichikawa (January 10, 1928)  [Reappointment] [Outside Director] [Independent Officer]	June 1986	Senior Managing Officer and Representative Director of The Mitsubishi Bank, Ltd.		
		June 1989	Senior Executive Vice President and Representative		
			Director of NIKON CORPORATION		
		June 1993	Vice Chairman of the Board and Representative		
			Director of NIKON CORPORATION		
		October 2001	Financial Advisor to Keio University	2,000	None
		April 2004	Director of the National University Corporation Tokyo		
11			Gakugei University		
11		May 2004	Outside Corporate Auditor of the Company		
		January 2008	Member of the Tokyo Metropolitan Public Interest		
			Corporation Council		
		May 2015	Outside Director of the Company (to present)		
	[Reason for nomination	on as candidatel		•	•

[Reason for nomination as candidate]

Mr. Isao Ichikawa has extensive experience and insight into overall management acquired as a representative director of a listed company. We nominate him as a candidate for Director in order for him to provide precise advice on the Company's management and since there is no problem with his independence in relationship with the Company. We believe he is suitable for continuing

to serve as an Outside Director of the Company.

		January 1960	Joined the Ministry of Health and Welfare		
		June 1986	Principal Counsellor of Cabinet Secretariat	ļ	
		June 1989	Director General of Children and Families Bureau,	!	
	Teijiro Furukawa		Ministry of Health and Welfare		
	(September 11, 1934)	June 1993	Vice-Minister of Health and Welfare	!	
	(September 11, 1754)	February 1995	Deputy Chief Cabinet Secretary	!	
	[Reappointment]	September 2003	Resigned from the position of Deputy Chief Cabinet	200	None
	[Outside Director]	•	Secretary		
10	-	July 2005	Executive President of Imperial Gift Foundation	!	
12	[Independent Officer]		Boshi-Aiiku-Kai		
		April 2015	Executive Chairman of Imperial Gift Foundation	!	
			Boshi-Aiiku-Kai (to present)		
		May 2015	Outside Director of the Company (to present)		

[Reason for nomination as candidate]

Mr. Teijiro Furukawa held key positions in the Ministry of Health and Welfare and has deep insight with regard to the Company's particular business. We nominate him as a candidate for Director in order for him to provide precise advice on the Company's management and since there is no problem with his independence in relationship with the Company. We believe he is suitable for continuing to serve as an Outside Director of the Company.

### (Notes)

- 1. The Company is engaged in the following transactions with the company at which Mr. Naruhito Higo serves concurrently as a representative director.
  - Noven Pharmaceuticals, Inc.: Research consignment
- 2. Messrs. Isao Ichikawa and Teijiro Furukawa are candidates for Outside Directors.
- 3. Messrs. Isao Ichikawa and Teijiro Furukawa, candidates for Outside Directors, satisfy the requirements of independent officers stipulated by Tokyo Stock Exchange, Inc., Nagoya Stock Exchange, Inc. and Fukuoka Stock Exchange, respectively, and the Company has notified these stock exchanges of them as independent officers.
- 4. At the conclusion of this General Meeting of Shareholders, Messrs. Isao Ichikawa and Teijiro Furukawa will have served for four years as Outside Directors of the Company.
- 5. The Company has entered into agreements with Messrs. Isao Ichikawa and Teijiro Furukawa in accordance with Article 427, Paragraph 1 of the Companies Act, to limit the liability for damages set forth in Article 423, Paragraph 1 of the same act to the amount stipulated by laws and regulations. If this proposal is approved, the Company plans to continue the said agreements with them.

## Proposal 3: Election of One Corporate Auditor

The term of office of Tetsuo Tokunaga, one of the total four Corporate Auditors, will expire at the conclusion of this General Meeting of Shareholders. Accordingly, the election of one Corporate Auditor is proposed.

The Board of Corporate Auditors has given its consent to this proposal.

The candidate for Corporate Auditor is as follows:

Name (Date of birth)	P	Past experience, positions, responsibilities and significant concurrent positions	Number of shares of the Company held	Special interests in the Company
Tetsuo Tokunaga (May 30, 1936)  [Reappointment] [Outside Corporate Auditor] [Independent Officer]	April 1961  June 1998  June 2003  June 2005  February 2008  May 2011	Joined Asahi Chemical Industry Co., Ltd. (Currently Asahi Kasei Corp.) Vice President & Representative Director of Asahi Kasei Corp. Executive Advisor of Asahi Kasei Corp. Advisor of Asahi Kasei Corp. Administrative Director of Pension Fund Association Outside Corporate Auditor of the Company (to present)	800	None

[Reason for nomination as candidate]

Mr. Tetsuo Tokunaga has extensive experience and insight into overall management acquired as a representative director of a listed company. We nominate him as a candidate for Corporate Auditor in order for him to provide precise advice on the Company's management and since there is no problem with his independence in relationship with the Company. We believe he is suitable for continuing to serve as an Outside Corporate Auditor of the Company.

#### (Notes)

- 1. Mr. Tetsuo Tokunaga is a candidate for Outside Corporate Auditor.
- 2. Mr. Tetsuo Tokunaga, candidate for Outside Corporate Auditor, satisfies the requirements of independent officers stipulated by Tokyo Stock Exchange, Inc., Nagoya Stock Exchange, Inc. and Fukuoka Stock Exchange, respectively, and the Company has notified these stock exchanges of him as an independent officer. At the conclusion of this General Meeting of Shareholders, he will have served for eight years as an Outside Corporate Auditor of the Company.
- 3. The Company has entered into an agreement with Mr. Tetsuo Tokunaga in accordance with Article 427, Paragraph 1 of the Companies Act, to limit the liability for damages set forth in Article 423, Paragraph 1 of the same act to the amount stipulated by laws and regulations. If this proposal is approved, the Company plans to continue the said agreement with him.